Seeking Alpha

the humble scribe

the humble scribe
Send Message
View as an RSS Feed
View the humble scribe's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead Sciences: Killing The Competition With Sovaldi; But Does This Make Gilead A One-Trick Pony? [View article]
    Too good to make the business sustainable? What rubbish!. No more treatment by the drug is needed is true for those who buy the product and are cured. But what about those who have hepatitis and need the drug to survive? Insurers are complaining that the drug is too expensive? When compared to what? What is the cost to the government of people needing a liver transplant? Surely curing people is less expensive than having them languish on a hospital bed to die.
    Jun 10 05:44 AM | 1 Like Like |Link to Comment
  • A Physician-Businessman's Views Of Gilead, With Emphasis On Sovaldi [View article]
    This is the kind of article that makes my joining Seeking Alpha worthwhile, not simply because it confirms my opinion on this stock but because of its lucid analysis of this blockbuster company. Thank you for sharing your insight with the public at large.
    Apr 8 05:54 AM | 2 Likes Like |Link to Comment
  • Baxter Splits: Let's Take A Closer Look [View article]
    If all shareholders who owned Baxter international a couple of decades or so ago still held today the shares of Edward's life sciences (EW) when they were spun off, they would be have been greatly rewarded. I am still long both stocks. Baxter is the gift that keeps on giving. Wow what a company!
    Mar 27 03:31 PM | 1 Like Like |Link to Comment
  • CA panel deems Sovaldi a "low value" treatment [View news story]
    The saying is ''build a new and more efficient mousetrap and they will come knocking at your door''. And Hepper Bozo here above is the proof of the efficiency. Now if only there were a couple of doctors suffering from liver desease sitting on this pannel perhaps the panel would come up with a different conclusion. We are talking here about a life saving drug folks.
    Mar 13 06:04 AM | Likes Like |Link to Comment
  • IAC/InterActiveCorp: Plenty Of Upside As Tinder Approaches 1B Daily Profile Views [View article]
    Thanks for this excellent article highlighting IACI's potential as a double bagger.

    Long IACI!
    Mar 6 11:25 AM | 2 Likes Like |Link to Comment
  • Is Nadella The Answer For Microsoft? [View article]
    Who was it that said that you should buy stocks in a company that can be run by an idiot because it may one day have an idiot as its CEO. I believe that there are some companies that have a multitude of good product lines and so much cash on hand that you ought to own them regardless. Microsoft is definitely one of those companies.
    Feb 3 08:51 AM | 1 Like Like |Link to Comment
  • ModernGraham Valuation Of Gilead Sciences [View article]
    Gilead's hepatitis C drug Sovaldi gets off to strong start • 9:15 AM
    •Total prescriptions (TRx) for Gilead's (GILD +1.3%) hepatitis C pill Sovaldi rose almost 70% to 1,764 in the week ended January 10, although it's worth pointing out that previous weeks included the holidays.

    The stock is up 2$ this morning on the news

    Disclaimer : Long GILD shares and options
    Jan 21 11:40 AM | Likes Like |Link to Comment
  • Encana: A Potential Low-Risk Double With A 4.7% Yield [View article]
    It is interesting to note that since this article was written back in June and 62 comments later, Encana has been down roughly 7%. Again, why would anyone want to invest in this dud when one could invest in anyone of the following Oil gas and equipment ETF's and record year to date double digit returns on your investment.
    XES up 28%, OIH up 28%, PJX up 29% IEO up 30%
    PXE up 23%
    XOP up 29%
    Encana, Dud it was for years, dud it is today and dud it will be tomorrow unless it's taken over by people who can run it right.
    Nov 5 04:19 PM | Likes Like |Link to Comment
  • Why Buy The Dow When You Can Buy This Single Stock? [View article]
    As an investor who recently purchased 500 PG shares at $81.50 I find cold comfort in your recommendation that over time this stock will outperform the DIA. At today's price of 77.13, I'm down a sizeable 5 percent in less than a month on a significant sum of money . The protection I got came in selling 5 October 82.5 covered calls at $ 3.00 at the same time that I bought the shares. Today I'm loking forward to delivering those shares in a couple months and making more on these options than on the stock.
    Aug 28 01:39 PM | Likes Like |Link to Comment
  • The State Of The Hepatitis C Pill Race: Gilead Vs. AbbVie [View article]
    This is from the Wallstreet journal:
    Gilead's profit rises 8.6% as its HIV drugs post gains
    --Company announces plans to seek approval for its first blood cancer drug in the fourth-quarter
    --Shares rise 5.6% after hours with news of a competitor's setback in hepatitis C
    (Updates throughout with details and company comment.)
    By Joseph Walker and Kristin Jones
    Gilead Sciences Inc.'s (GILD:$60.86,00$0.98,0... second-quarter profit rose 8.6% as the drug company posted sales gains from its core business of antiviral HIV treatments and made continued progress in its expansion into other disease areas.
    Gilead is one of the world's largest makers of HIV drugs, but as sales growth in that area has slowed, the company has moved aggressively in recent years into hepatitis C and cancer.
    On a conference call Thursday, company executives said Gilead would seek approval in the fourth-quarter for its experimental drug idelalisib as a treatment for indolent non-Hodgkin's lymphoma, which would begin to establish the company as a player in the growing market for blood cancer treatments.
    "We are going to be very committed commercially to this launch; we will build a business unit for oncology," said Kevin Young, executive vice president of commercial operations, during a conference call with analysts. "We see this as a strong, long-term commitment to the world of oncology."
    Meanwhile, the company's position as a leader in the race to develop new pill therapies for hepatitis C was boosted after a competitor, Vertex Pharmaceuticals Inc. (VRTX:$87.62,00$2.36,0... , announced that a key drug program had been put on partial clinical hold by the U.S. Food and Drug Administration because of safety concerns.
    Gilead's experimental oral hepatitis C treatment sofosbuvir received priority- review status from the U.S. Food and Drug Administration last month, a designation that may speed its evaluation. The European Medicines Agency has also put the drug on an accelerated assessment schedule.
    Gilead shares rose 5.6% to $64.30 in after-hours trading; through the close, the stock was up 65.7% year-to-date.
    Vertex shares fell 9% to $79.66.
    Until recently, the company's cancer program has been overshadowed by its antiviral regimens. That may begin to change as Gilead moves closer to potentially gaining approval for its drug, which could compete against an experimental therapy being developed by Pharmacyclics Inc. (PCYC:$103.71,00$2.21,... and Johnson & Johnson (JNJ:$92.57,00$0.21,00... .
    "Gilead has a very good drug and it hasn't been getting any credit for it," said David Ferreiro, an Oppenheimer & Co. analyst. "The value proposition just got a little richer."
    In the latest period, sales of Gilead's HIV treatment Complera more than doubled from a year earlier, to $188.7 million, while Stribild contributed $99.4 million to sales.
    Overall, Gilead reported a profit of $772.6 million, up from $711.6 million a year earlier. On a per-share basis, earnings were flat at 46 cents as the number of shares outstanding grew. Excluding acquisition costs and other one-time items, the company reported a profit of 50 cents a share, up from 49 cents a year ago.
    Revenue rose 15% to $2.66 billion. Analysts polled by Thomson Reuters expected per-share earnings of 50 cents on revenue of $2.66 billion.
    Total costs and expenses jumped 20% in the latest period, as input costs and research and development expenses increased.
    Write to Joseph Walker at Joseph.Walker@wsj.com
    Jul 25 10:16 PM | 1 Like Like |Link to Comment
  • Consider Biotech Gilead Sciences Because Of Atripla, Sofosbuvir And Great R&D [View article]
    Gilead's profit rises 8.6% as its HIV drugs post gains
    --Company announces plans to seek approval for its first blood cancer drug in the fourth-quarter
    --Shares rise 5.6% after hours with news of a competitor's setback in hepatitis C
    (Updates throughout with details and company comment.)
    By Joseph Walker and Kristin Jones
    Gilead Sciences Inc.'s (GILD:$60.86,00$0.98,0... second-quarter profit rose 8.6% as the drug company posted sales gains from its core business of antiviral HIV treatments and made continued progress in its expansion into other disease areas.
    Gilead is one of the world's largest makers of HIV drugs, but as sales growth in that area has slowed, the company has moved aggressively in recent years into hepatitis C and cancer.
    On a conference call Thursday, company executives said Gilead would seek approval in the fourth-quarter for its experimental drug idelalisib as a treatment for indolent non-Hodgkin's lymphoma, which would begin to establish the company as a player in the growing market for blood cancer treatments.
    "We are going to be very committed commercially to this launch; we will build a business unit for oncology," said Kevin Young, executive vice president of commercial operations, during a conference call with analysts. "We see this as a strong, long-term commitment to the world of oncology."
    Meanwhile, the company's position as a leader in the race to develop new pill therapies for hepatitis C was boosted after a competitor, Vertex Pharmaceuticals Inc. (VRTX:$87.62,00$2.36,0... , announced that a key drug program had been put on partial clinical hold by the U.S. Food and Drug Administration because of safety concerns.
    Gilead's experimental oral hepatitis C treatment sofosbuvir received priority- review status from the U.S. Food and Drug Administration last month, a designation that may speed its evaluation. The European Medicines Agency has also put the drug on an accelerated assessment schedule.
    Gilead shares rose 5.6% to $64.30 in after-hours trading; through the close, the stock was up 65.7% year-to-date.
    Vertex shares fell 9% to $79.66.
    Until recently, the company's cancer program has been overshadowed by its antiviral regimens. That may begin to change as Gilead moves closer to potentially gaining approval for its drug, which could compete against an experimental therapy being developed by Pharmacyclics Inc. (PCYC:$103.71,00$2.21,... and Johnson & Johnson (JNJ:$92.57,00$0.21,00... .
    "Gilead has a very good drug and it hasn't been getting any credit for it," said David Ferreiro, an Oppenheimer & Co. analyst. "The value proposition just got a little richer."
    In the latest period, sales of Gilead's HIV treatment Complera more than doubled from a year earlier, to $188.7 million, while Stribild contributed $99.4 million to sales.
    Overall, Gilead reported a profit of $772.6 million, up from $711.6 million a year earlier. On a per-share basis, earnings were flat at 46 cents as the number of shares outstanding grew. Excluding acquisition costs and other one-time items, the company reported a profit of 50 cents a share, up from 49 cents a year ago.
    Revenue rose 15% to $2.66 billion. Analysts polled by Thomson Reuters expected per-share earnings of 50 cents on revenue of $2.66 billion.
    Total costs and expenses jumped 20% in the latest period, as input costs and research and development expenses increased.
    Write to Joseph Walker at Joseph.Walker@wsj.com
    Jul 25 10:12 PM | Likes Like |Link to Comment
  • EMC and VMware (VMW) have made their rumored spinoff official. Called the Pivotal Initiative, VMware says it will feature not only the Greenplum, Cloud Foundry, SpringSource, and Gemstone units, as has been reported, but also EMC's Pivotal Labs Web/mobile software development tool business, and VMware's Cetas big data analytics software unit. As expected, ex-VMware CEO Paul Maritz will be in charge. Virtually anything offered by VMware/EMC that's aimed at Web/cloud developers or big data projects is in the mix. If an IPO happens in the future, it could be a big one. [View news story]
    Strange how the price of EMC shares has been rangebound for the past couple of years and shareholders are not benefiting from this appeciation in the intrinsic value of EMC.
    Jul 8 11:34 AM | Likes Like |Link to Comment
  • Encana: A Potential Low-Risk Double With A 4.7% Yield [View article]
    They always warn us that ''past performance is no guarantee of future results''. In this case we should hope that this saying is true. This stock has been a dud for at least the past 10 years. Its great to have a yield of 4.65%but when a stock's keeps going down for as long as one could remember, you'r better off investing your money elsewhere.
    Jun 27 09:32 AM | 2 Likes Like |Link to Comment
  • Bill Gross's Misguided Diagnosis Of America's Economic Problems [View article]
    Derryl,

    Your statement ''I am just joining Kostohryz in saying that it is not the "moral responsibility" of money borrowers to pay higher than market interest rates...'' is well taken,but unfortunately it doesn't help retirees on fixed income who can hardly make ends meet on their CD's and Social security cheques.
    Jun 14 12:22 PM | Likes Like |Link to Comment
  • Bill Gross's Misguided Diagnosis Of America's Economic Problems [View article]
    James,

    Thanks for your great article, but what to you advise someone like this 80 year old lady do do in this difficult time? Certainly buying stocks only can be quite a risky proposition.
    Jun 14 11:57 AM | 2 Likes Like |Link to Comment
COMMENTS STATS
141 Comments
135 Likes